EMPA-KIDNEY is a clinical trial initiated by scientists based at the Medical Research Council Population Health Research Unit (PHRU), which is part of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at the University of Oxford. The Oxford team is being supported by an academic collaboration spanning 7 countries, including the United States, Canada, Germany, China, Japan, Malaysia and the United Kingdom. EMPA-KIDNEY requires at least 5000 volunteers with chronic kidney disease to participate in the trial, as well as many kidney, diabetes and other medical speciality healthcare teams around the world to help make the study possible.
Information about the study for people with chronic kidney disease can be found in the FAQ section.
Information about the study and empagliflozin for healthcare professionals can be found in the Professionals section.